Post
PRO-1107 by ProfoundBio Suzhou for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer). …
PRO-1107 by ProfoundBio Suzhou for Fallopian Tube Cancer: Likelihood of Approval
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, …
PRO-1107 by ProfoundBio Suzhou for Non-Small Cell Lung Cancer: Likelihood of Approval
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Non-Small Cell Lung Cancer. According to …
PRO-1107 by ProfoundBio Suzhou for Endometrial Cancer: Likelihood of Approval
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase …
PRO-1107 by ProfoundBio Suzhou for Solid Tumor: Likelihood of Approval
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Solid Tumor. According to GlobalData, Phase …
PRO-1107 by ProfoundBio Suzhou for Bladder Cancer: Likelihood of Approval
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Bladder Cancer. According to GlobalData, Phase …
PRO-1107 by ProfoundBio Suzhou for Gastric Cancer: Likelihood of Approval
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Gastric Cancer. According to GlobalData, Phase …
DF-4101 by AbbVie for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
DF-4101 is under clinical development by AbbVie and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC). …
DF-4101 by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval
DF-4101 is under clinical development by AbbVie and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, …
DF-4101 by AbbVie for Renal Cell Carcinoma: Likelihood of Approval
DF-4101 is under clinical development by AbbVie and currently in Phase I for Renal Cell Carcinoma. According to GlobalData, Phase …
DF-4101 by AbbVie for Solid Tumor: Likelihood of Approval
DF-4101 is under clinical development by AbbVie and currently in Phase I for Solid Tumor. According to GlobalData, Phase I …
RG-6315 by Genentech USA for Inflammation: Likelihood of Approval
RG-6315 is under clinical development by Genentech USA and currently in Phase I for Inflammation. According to GlobalData, Phase I …
GH-21 by HUYA Bioscience International for Non-Small Cell Lung Cancer: Likelihood of Approval
GH-21 is under clinical development by HUYA Bioscience International and currently in Phase I for Non-Small Cell Lung Cancer. According …
HU-6 by Rivus Pharmaceuticals for Hypertriglyceridemia: Likelihood of Approval
HU-6 is under clinical development by Rivus Pharmaceuticals and currently in Phase II for Hypertriglyceridemia. According to GlobalData, Phase II …
Lirafugratinib hydrochloride by Relay Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Lirafugratinib hydrochloride is under clinical development by Relay Therapeutics and currently in Phase II for Human Epidermal Growth Factor Receptor …